肿瘤细胞治疗研究
英文原题：Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy.
经典型霍奇金淋巴瘤（cHL）是一种在生物学和临床上独特的恶性肿瘤，其特征是稀少的霍奇金和 Reed-Sternberg（HRS）细胞被密集而多样的炎症浸润所包围。
经典型霍奇金淋巴瘤（cHL）在生物学和临床上具有独特性，其特征是少量霍奇金和 Reed-Sternberg（HRS）细胞被致密、多样的炎症细胞浸润包围。这些恶性细胞通过代谢重编程和免疫逃逸策略主动重塑肿瘤微环境（TME）。本综述总结代谢改变如何促进 cHL 肿瘤存活、免疫功能障碍及治疗耐药的现有认识，讨论旨在干扰这些过程的新型治疗方法，并考察代谢干预与免疫策略联合的潜力，包括免疫检查点抑制剂（CPI）、表观遗传调节剂、双特异性抗体以及 CAR-T/CAR-NK 细胞疗法；这些策略或可克服耐药并增强抗肿瘤应答。目前有多种药物正在研究其调节免疫细胞代谢、恢复有效免疫监视的能力。总体而言，同时靶向肿瘤和免疫细胞区室中的代谢弱点，是改善复发或难治性 cHL 患者临床结局的有前景、多层面的策略。
Classical Hodgkin lymphoma (cHL) is a biologically and clinically unique malignancy characterized by rare Hodgkin and Reed-Sternberg (HRS) cells surrounded by a dense and diverse inflammatory infiltrate. These malignant cells actively reshape the tumor microenvironment (TME) through metabolic reprogramming and immune evasion strategies. This review synthesizes current knowledge on how metabolic alterations contribute to tumor survival, immune dysfunction, and therapeutic resistance in cHL. We discuss novel therapeutic approaches aimed at disrupting these processes and examine the potential of combining metabolic interventions with immune-based strategies-such as immune checkpoint inhibitors (CPIs), epigenetic modulators, bispecific antibodies, and CAR-T/CAR-NK cell therapies-which may help overcome resistance and enhance anti-tumor responses. Several agents are currently under investigation for their ability to modulate immune cell metabolism and restore effective immune surveillance. Altogether, targeting metabolic vulnerabilities within both tumor and immune compartments offers a promising, multifaceted strategy to improve clinical outcomes in patients with relapsed or refractory cHL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
